2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

J Steffel, R Collins, M Antz, P Cornu, L Desteghe… - EP …, 2021 - academic.oup.com
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

[HTML][HTML] Cardiovascular research using the Korean national health information database

EK Choi - Korean circulation journal, 2020 - ncbi.nlm.nih.gov
Abstract The Korean National Health Information Database (NHID) contains nationwide
claims data, including sociodemographic data, health care utilization, health screening data …

Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population …

WCY Lau, CO Torre, KKC Man, HM Stewart… - Annals of Internal …, 2022 - acpjournals.org
Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Off-label dosing of non–vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation

YH Chan, TF Chao, SW Chen, HF Lee, YH Yeh… - Heart rhythm, 2020 - Elsevier
Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Comparing warfarin and 4 direct oral anticoagulants for the risk of dementia in patients with atrial fibrillation

SR Lee, EK Choi, SH Park, JH Jung, KD Han, S Oh… - Stroke, 2021 - Am Heart Assoc
Background and Purpose: Atrial fibrillation is a risk factor for dementia, and oral
anticoagulant use is associated with a decreased risk of dementia in patients with atrial …

[HTML][HTML] Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort …

M Grymonprez, TL De Backer, X Bertels… - Frontiers in …, 2023 - frontiersin.org
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Comparative effectiveness and safety of non–vitamin K antagonist oral anticoagulants in atrial fibrillation patients

W Zhu, Z Ye, S Chen, D Wu, J He, Y Dong, GYH Lip… - Stroke, 2021 - Am Heart Assoc
Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

[HTML][HTML] Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis

TM Rhee, SR Lee, EK Choi, S Oh… - Frontiers in …, 2022 - frontiersin.org
Background Data on different direct oral anticoagulants (DOACs) in atrial fibrillation (AF)
patients with renal impairment are insufficient. We aimed to perform pairwise and network …

Protective effect of proton‐pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta‐analysis

HJ Ahn, SR Lee, EK Choi, TM Rhee… - British journal of …, 2022 - Wiley Online Library
Aims The evidence of a protective effect of proton‐pump inhibitor (PPI) in oral anticoagulant
(OAC)‐treated patients against gastrointestinal bleeding (GIB) is still lacking. We conducted …

Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea

M Son, J Seo, S Yang - Hypertension, 2020 - Am Heart Assoc
The severe acute respiratory syndrome coronavirus 2 is known to infect host cells by
interacting with ACE2 (angiotensin-converting enzyme 2) expressed in the respiratory …